Background: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe pulmonary arterial hypertension, but adverse effects like infusion site pain can lead to treatment discontinuation. Objectives: The objective of this study was to evaluate safety, tolerability and clinical effects of a rapid up-titration dosing regimen of subcutaneous treprostinil using proactive infusion site pain management. Methods: Effects of rapid up-titration dosing regimen on tolerability and clinical parameters were evaluated in this 16-week, open-label multi-centre study. Results: Thirty-nine patients with idiopathic or heritable pulmonary arterial hypertension on stable treatment with oral pulmonary arterial hypertension-approved drugs (90% on dual combination therapy) were included. Patients achieved a median treprostinil dosage of 35.7 ng/kg/min after 16 weeks. A good overall safety profile was demonstrated with 3 patients (8%) withdrawing due to infusion site pain, which occurred in 97% of patients. After 16 weeks, median 6-min walking distance, cardiac index, pulmonary vascular resistance, and tricuspid annular plane systolic excursion improved. Conclusions: Rapid up-titration of subcutaneous treprostinil was well tolerated, achieving a clinically effective dose associated with improvement of exercise capacity and haemodynamics after 16 weeks. A rapid dose titration regimen and proactive infusion site pain management may improve the handling of this therapy and contribute to better treatment outcome.

Keywords:
Pulmonary arterial hypertension, Subcutaneous infusion, Treprostinil
1.
Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901.
2.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
3.
Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ: A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet 2008;47:611-618.
4.
Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
5.
Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, et al: Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-1643.
6.
Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al: Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28:1195-1203.
7.
Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, et al: Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012;31:735-743.
8.
White RJ, Levin Y, Wessman K, Heininger A, Frutiger K: Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ 2013;3:611-621.
9.
Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM: Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011;30:982-989.
10.
Mathier MA, McDevitt S, Saggar R: Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant 2010;29:1210-1217.
11.
Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Kuwana M, et al: Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension. PLoS One 2015;10:e0121894.
12.
Tokunaga N, Ogawa A, Ito H, Matsubara H: Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol DOI: 10.1016/j.jjcc.2015.11.012.
13.
American Thoracic Society, Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
14.
Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, et al: Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007;132:757-763.
15.
Dario A, Scamoni C, Picano M, Fortini G, Cuffari S, Tomei G: The infection risk of intrathecal drug infusion pumps after multiple refill procedures. Neuromodulation 2005;8:36-39.
16.
Ewert R, Halank M, Bruch L, Ghofrani HA: A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy. Am J Respir Crit Care Med 2012;186:1196-1198.
17.
Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro S, Tarver J, Zwicke D, Feldman J, Chakinala M, Frantz R, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin L: Treprostinil administered using a fully implantable programmable intravascular delivery system: results of the delivery for PAH trial. Chest 2014;146:862A.
18.
United Therapeutics Corp: United Therapeutics Summary of Product Characteristics. 22. Remodulin 1 mg/ml solution for infusion. August 2014.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.